Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Reeder CB, et al. Among authors: bergsagel pl. Leukemia. 2009 Jul;23(7):1337-41. doi: 10.1038/leu.2009.26. Epub 2009 Feb 19. Leukemia. 2009. PMID: 19225538 Free PMC article. Clinical Trial.
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, Kukreti V, Wei E, Leung-Hagesteijn C, Li ZH, Brandwein J, Pantoja M, Johnston J, Gibson S, Hernandez T, Spaner D, Trudel S. Chen CI, et al. Among authors: bergsagel pl. J Clin Oncol. 2011 Mar 20;29(9):1175-81. doi: 10.1200/JCO.2010.29.8133. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189385 Free PMC article. Clinical Trial.
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium; Getz G, Golub TR. Lohr JG, et al. Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015. Cancer Cell. 2014. PMID: 24434212 Free PMC article.
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Reeder CB, et al. Among authors: bergsagel pl. Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30. Br J Haematol. 2014. PMID: 24974945 Free article. Clinical Trial. No abstract available.
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.
Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. Jensen JL, et al. Among authors: bergsagel pl. Cancer Immunol Res. 2015 Aug;3(8):881-90. doi: 10.1158/2326-6066.CIR-15-0025-T. Epub 2015 May 4. Cancer Immunol Res. 2015. PMID: 25941352 Free PMC article.
263 results